Postoperative residual neuromuscular blockade and hypoventilation after rocuronium and sugammadex or neostigmine for kidney transplantation: A randomized clinical trial
Authors' conclusion
Sugammadex was non-inferior to neostigmine on the incidence of RNMB and hypoventilation, even after adjusting for RNMB, opioids, and other covariates, in PACU and up to three days after kidney transplantation.
Study context
- Population
- Adults undergoing renal transplantation with rocuronium-based neuromuscular blockade (NMB)ITT analysis
- Participants
- 84 adults
- Comparison
- Sugammadex vs neostigmine reversal of rocuronium NMB
- Sugammadexn = 42
- Neostigminen = 42reference
- Primary endpoint
- Hypoventilation episodes (≥ 1-min-long, minute ventilation <40% of predicted) by continuous non-invasive bioimpedance ventilation monitoring in post-anesthesia care unit (PACU)
Methodological detailssingle-center, double-blind
- Single-center
- Double-blind
Primary result
As reported in the abstract
Hypoventilation incidence in PACU
P = 1.000
Further findings
Hypoventilation incidence on the ward · up to three days
P = 1.000
TOFR<0.9 events in PACU (normalized to baseline)
P = 0.127
TOFR<0.9 events on the ward (normalized to baseline)
P = 0.425
Original publication
Postoperative residual neuromuscular blockade and hypoventilation after rocuronium and sugammadex or neostigmine for kidney transplantation: A randomized clinical trial. J Clin Anesth. Published 14 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →